Navigation Links
Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
Date:4/21/2008

NANJING, China, April 22 /Xinhua-PRNewswire Simcere Pharmaceutical Group (NYSE: SCR; ''Simcere''), a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in China, today announced that it has signed a definitive agreement to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical Co. Ltd. for a total cash consideration of RMB64.82 million (US $9.26 million). This transaction is consistent with Simcere's strategy to focus on first-to-market and innovative new drugs and expand its anti-cancer product portfolio.

Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained release anti-tumor implants. Its key product SinoFuan (fluorouracil implant), is proven to effectively inhibit the growth of tumors, and is the only sustained release anti-tumor implant approved by the State Food and Drug Administration (SFDA). SinoFuan is commonly used to treat cancers of the digestive tract and is a favored choice for use during surgery. No similar product exists on the Chinese market today. Distribution of SinoFuan through Simcere's established marketing channels will enhance Simcere's offerings in the anti-cancer drug market, benefit cancer patients across China and create greater value for Simcere shareholders.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR; Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases and currently has more than 12 pipeline products. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For more information, please contact:

In China:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 x8818

Email: zhaozhigang@simcere.com

Kejia Wu

Brunswick Group

Tel: +86-10-6566-4651

Email: kwu@brunswickgroup.com

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5033

Email: jlo@brunswickgroup.com

In the United States:

Michael Guerin

Brunswick Group

Tel: +1-212-333-3810

Email: mguerin@brunswickgroup.com


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
2. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
3. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
4. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
5. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
6. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
7. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2008 Financial Results
8. Law Offices of Howard G. Smith Announces 21 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Vertex Pharmaceuticals Inc.
9. Amylin Pharmaceuticals Reports First Quarter Financial Results
10. Complementary Excerpt Available from Best Practices: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications
11. Best Practice Database: Valuable Strategies for Pharmaceutical Product Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Santa Barbara, CA (PRWEB) , ... January 21, ... ... through its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events ... enlivening festivities for alumni, family, friends, and community. “Coming Home 2017” will ...
(Date:1/20/2017)... Missoula, MT (PRWEB) , ... January 20, 2017 , ... Spectrum Aquatics Launches New ADA ... use, saving deck space. Since the lift is mounted on wheels, it can be wheeled ... a lock down kit, to fasten to the deck. "We have transformed the feedback from ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted ... had a successful January ECRM Trade Show in Hilton Head, SC. , Bionic ... it to provide its products to all clients at reasonable prices. At the ECRM ...
(Date:1/20/2017)... Aliso Viejo, California (PRWEB) , ... January 20, 2017 , ... ... and easy to use inside of Final Cut Pro X," said Christina Austin - ... filmed on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and ...
(Date:1/20/2017)... ... ... examination of how God handles sin, including how to let go of lingering guilt and ... ten long years has been waiting to release this powerful insight about forgiveness that the ... the Lord for over twenty years, and he has been preaching and teaching the Word ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Research and Markets has announced the ... and Future" report to their offering. ... This research service on the global ... and provides a snapshot of the key participants in the market. ... provided from 2016 to 2020. The market is expected to grow ...
(Date:1/20/2017)... , VAE, January 20, 2017 ... stark gestiegenen Bedarf an Nothilfe   Die internationale ... Platz für Hilfsgüter zu schaffen   ... und Premierminister der VAE sowie Herrscher von ... der internationalen Stadt der Hilfe (International Humanitarian City IHC) ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 ... USD 233.7 billion by 2025, according to a ... market is anticipated to be predominantly driven by ... resulting into the large-scale production of new and ... the influx of drugs at an unprecedented rate ...
Breaking Medicine Technology: